|
Investments in Variable Interest Entities (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Dec. 31, 2011
|
Sep. 30, 2012
Knopp [Member]
|
Sep. 30, 2011
Knopp [Member]
|
Sep. 30, 2012
Knopp [Member]
|
Sep. 30, 2011
Knopp [Member]
|
Sep. 30, 2012
Neurimmune [Member]
|
Sep. 30, 2011
Neurimmune [Member]
|
Sep. 30, 2012
Neurimmune [Member]
|
Sep. 30, 2011
Neurimmune [Member]
|
Dec. 31, 2010
Common Class B [Member]
Knopp [Member]
|
|
| Investment in Variable Interest Entities (Textual) [Abstract] | ||||||||||||||
| Purchase of common shares in variable interest entities | 30.00% | |||||||||||||
| Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement | $ 255,000,000 | $ 345,000,000 | ||||||||||||
| Percentage of funding for R&D cost required in support of the collaboration agreement | 100.00% | 100.00% | ||||||||||||
| Research and development expense | 304,217,000 | 301,391,000 | 989,738,000 | 880,668,000 | 15,700,000 | 21,800,000 | 58,900,000 | 36,500,000 | 3,400,000 | 1,500,000 | 8,500,000 | 6,300,000 | ||
| Payment recognized as a charge to noncontrolling interests, net of tax | 10,000,000 | 15,000,000 | ||||||||||||
| Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 9,300,000 | $ 9,300,000 | $ 14,600,000 | |||||||||||